<DOC>
	<DOCNO>NCT02712346</DOCNO>
	<brief_summary>The primary goal study determine safety tolerability ambrisentan . It also expect ambrisentan improve blood flow lung , decrease inflammation , reduce pain sickle cell patient . An additional goal evaluate use select biomarkers evaluate sickle nephropathy .</brief_summary>
	<brief_title>The Role Endothelin-1 Sickle Cell Disease</brief_title>
	<detailed_description>The purpose study test hypothesis endothelin antagonist ( ETA ) receptor blockade use ambrisentan safe , tolerable , improve kidney function/albuminuria patient sickle cell disease ( SCD ) . The investigator anticipate reduction proteinuria , decrease tricuspid regurgitation jet ( TRJ ) velocity , reduction inflammatory marker , improvement forearm blood flow , improvement nociception/pain . The primary efficacy endpoint choose effect ETA receptor blockade reduction microalbuminuria base upon finding diabetic nephropathy , similar pathogenesis sickle nephropathy . A 30 % reduction proteinuria rather conservative realistic base upon result study ETA receptor blockade diabetic nephropathy consistently result 40-45 % reduction proteinuria . Pre-clinical data show change detect urinary nephrin excretion overt proteinuria observe model chronic ET-1 elevation . Furthermore , tubular injury occur result intrarenal vaso-occlusive crisis ( VOC ) expect increase level renal tubular injury marker , neutrophil gelantinase-associated lipocalin ( NGAL ) , kidney injury molecule-1 ( KIM-1 ) , netrin . Treatment ambrisentan would expect attenuate change . Dr. Jennifer Pollock , extensive experience biomarker assay include ET-1 . Dr. Pollock run bio-analytical core lab two PO1s publish extensively similar method human animal sample . Additional rationale project base recent 24-hour urine result creatinine clearance total protein excretion 97 patient sickle cell anemia ( Hb SS ) sickle beta zero thalassemia ( SB0-thalassemia ) follow Augusta Sickle Cell Clinic . These patient range age 19-63 year ( 52 female , 45 male ) . Of , 17 ( 18 % ) microalbuminuria define 24-hour albumin excretion 150-300 mg , 34 ( 36 % ) macroalbuminuria ( &gt; 300 mg albumin excretion/24-hours ) , thus 54 % patient microalbuminuria macroalbuminuria 46 % normo albuminuric . 58 patient ( 58 % ) chronic hydroxyurea therapy . 9 patient angiotensin convert enzyme inhibitor ( ACEi ) 20 angiotensin receptor blocker ( ARBs ) ( total 30 % ) . 55 patient ( 57 % ) glomerular hyperfiltration ( creatinine clearance &gt; 120 ml/min ) . There age related decline glomerular filtration rate ( GFR ) observe . The number patient normo albuminuria show sharp decline age indicative progression sickle nephropathy . Recent study pain SCD lead change perception . Approximately 50 % patient report experience daily , chronic pain . In addition , issue relate centralization neuropathic pain patient population begin gain increase attention . A large body evidence suggest endothelin-1 play important role enhance pain stimuli nociception various condition . This mediate ETA receptor . Berkeley SCD transgenic mouse hyperalgesia show rationale preliminary data section Aim 2 ETA receptor blockade reverse hyperalgesia towards normal . As part ongoing National Institute Minority Health Health Disparities ( NIMHD ) fund study pain genetic correlate ( study reference : 1 P20 MD003383-01 ) , investigator find SCD patient display significant hyperalgesia measure pressure pain algometer test . The test do three different anatomic site patient ( n=38 ) control ( n=20 ) show SCD patient perceive pain significantly low pressure compare control ( masseter : 157.7 kilopascal ( kPa ) patient , 214.4 kPa control , p=0.017 ; ulna : 299.1 kPa patient , 477.5 kPa control , p=0.0018 ; trapezius : 290.1 kPa patient , 462.8 kPa control , p=0.02 ) . These data suggest hyperalgesia present vast majority SCD patient constitute objective parameter monitor study . Protocol-required assessment perform every study visit include : physical exam , vital sign , con medication review , study drug accountability , adverse event review , pain diary completion , pregnancy test applicable . Protocol-required assessment perform specify study visit include : collection blood urine safety efficacy test ; electrocardiogram ( ECG ) ; echocardiogram ( echo ) ; Quantitative Sensory Testing ( pressure pain threshold via algometer , cutaneous mechanical pain via monofilament , thermal test via Q-Sense Small Fiber Test ) ; transcranial Doppler ( TCD ) ; forearm blood flow measurement ; skin blood flow measurement ; completion quality life questionnaire . Description Procedures : Sensory Testing : Patients also undergo sensory test baseline end study period . Sensory test include : 1 ) Pressure pain threshold measure hand-held , digital algometer describe Fillingim et al three different anatomical site : center right upper trapezius , right masseter , right ulna ; 2 ) Cutaneous mechanical pain testing- Assessment temporal summation mechanical pain do use nylon monofilaments test dorsum hand . ; 3 ) Thermal sensory testing perform use Q-Sense Small Fiber Test , offer scientifically validate measure warm , cool heat-pain thermal sensory threshold . Pain Diaries/Questionnaires : Patients ask complete daily pain diary described PISCES study . The evaluation pain diary perform Dr. Robert Gibson research staff . In addition , investigator also incorporate two pre/post measure examine effect pain functional performance quality life . The Assessment Motor Process Skills ( AMPS ) well-established functional assessment . This assessment demonstrate ability discriminate healthy control wide spread chronic pain . It also demonstrate ability measure change follow intervention . The investigator also measure patient 's quality life Adult Sickle Cell Quality Life Measurement Information System ( ASCQ-Me ) . This quality life assessment specifically develop sickle cell population . Dr. Robert Gibson train experience ASCQ-Me certify administer AMPS . Echocardiogram tricuspid regurgitation jet ( TRJ ) Velocity Measurement : A transthoracic echocardiogram measurement TRJ velocity pulmonary artery systolic pressure perform baseline ( unless obtain clinically within 6 month Day 1 ) end study . Electrocardiogram : An electrocardiogram ( ECG ) test measure electrical activity heart . An ECG do safety measure baseline , Day 8 visit , end study , although ambrisentan know prolong correct QT interval ( QTc ) . Forearm Blood Flow Measurement : Brachial artery flow-mediated dilation ( FMD ) perform accordance recent tutorial ultrasound assessment FMD . Patients test fasting condition control environment baseline end study period . Skin Blood Flow Measurement : Skin blood flow measure non-invasively use low frequency laser image camera and/or small skin probe . Ring-shaped probe 1.5 inch wide place forearm sticky tape . One ring fill approximately 2 ml ( 1/2 teaspoon ) water local heat others use iontophoresis . For local heat , investigator heat water ring 42°C ( 107°F ) 44°C ( 111°F ) wait approximately 30 minute increase skin blood flow become stable . Iontophoresis technique delivers vasoactive drug 1 mm deep skin use low level electrical current . The advantage technique non-invasive drug go body , remain surface skin . We use 1-2 % solution either acetylcholine , sodium nitroprusside , N-nitro-L-arginine methyl ester ( L-NAME ) ( vasoactive substance ) increase decrease skin blood flow . Multiple short current ( 10-180 second ) perform approximately 1 minute apart . Investigators monitor skin blood flow ring forearm arterial blood flow test describe well local heat iontophoresis . Blood Urine Measurement : Lab test perform safety/ efficacy assessment specify study visit include complete blood count ( CBC ) , complete metabolic panel ( CMP ) , spot urine albumin-creatinine ratio , 24-hour urine , pregnancy testing , biomarkers , inflammatory marker . Transcranial Doppler ( TCD ) : Pre- post-treatment TCD perform assess velocity cerebral blood flow . This non-invasive test perform subject lie involves use sound wave ass macro-circulation head . A transducer use hear record result .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>1 . SS Sβothalassemia 2 . Age 1865 year 3 . Microalbuminuria ( 24hour albumin 150300 mg ) macroalbuminuria ( 24hour albumin &gt; 300 mq ) 4 . Subjects Stage 1 , II , III chronic kidney disease ( CKD ) 5 . Subjects hydroxyurea , ACE inhibitor ( ACEi ) , angiotensin receptor blocker ( ARBs ) period 3 month great 6 . Females child bear potential must agree use two form birth control one barrier method ; abstinence acceptable form birth control 1 . Other genotype SCD 2 . History renal transplant 3 . Chronic kidney disease ( Stage IV V include patient hemo dialysis peritoneal dialysis ) 4 . Patients chronic transfusion therapy 5 . Uncontrolled/poorly controlled hypertension history hypertension predate proteinuria 6 . Known history HIV , Hepatitis C , and/or diabetes 7 . Peripheral edema 8 . History congestive heart failure pulmonary edema 9 . Recent history coronary artery disease 10 . Pregnant breast feed 11 . Alanine Aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3fold upper limit normal 12 . Albumin &lt; 2.5 gm/dl 13 . Hemoglobin &lt; 6 gm/dL 14 . History noncompliance medication clinic visit ; Inability give informed consent ; Patient deem ineligible unsuitable judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Sickle Cell Thalassemia</keyword>
	<keyword>Sickle Beta Thalassemia</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Sickle nephropathy</keyword>
</DOC>